Symbiomix assembled clinical investigators and study coordinators in Dallas, Texas, for an Investigator Meeting in preparation for initiating a Phase 2 clinical trial of SYM-1219 in women with bacterial vaginosis (BV). SYM-1219 is being developed as the first oral one-and-done treatment for BV in the U.S. The trial will be a multi-center, prospective, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of two different doses of SYM-1219 in approximately 210 women with BV. Symbiomix’s Chief Medical Officer, Carol J. Braun, M.D., commented, “We are excited to have reached this important milestone in the development of SYM-1219 for this indication. The enthusiasm evident at this meeting underscores how SYM-1219 could represent an important advance in the treatment of this common yet underappreciated disease.”